Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | FGB | P02675 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148339 | 0.82 | BRD4 (0.49) | TSHRHTTBRD4MAPTALDH1A1 | |
| SCHEMBL10148344 | 0.81 | METAP1 (0.41) | TDP2BRD4MAPTMETAP1 | |
| SCHEMBL651424 | 0.80 | MAPT (0.45) | GABRA1GABRB1GABRA3GABRB2TSHR | |
| SCHEMBL795467 | 0.78 | ESR1 (0.40) | GABRA1GABRB1GABRA3GABRB2TSHR | |
| SCHEMBL31537527 | 0.78 | ESR1 (0.40) | GABRA1GABRB1GABRA3GABRB2TSHR | |
| SCHEMBL30663973 | 0.76 | TDP2 (0.40) | TDP2BRD4MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3310487 | 0.76 | TDP2 (0.40) | TDP2BRD4MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3498263 | 0.73 | ALDH1A1 (0.36) | GABRA1GABRB1GABRA3GABRB2TSHR | |
| SCHEMBL4769228 | 0.70 | ALDH1A1 (0.39) | TSHRHTTBRD4MAPTALDH1A1 | |
| SCHEMBL30975233 | 0.69 | MAPT (0.47) | GABRA1GABRB1GABRA3GABRB2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | GABRA1 236/4885GABRB1 263/4885GABRA3 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.